查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715480

胚胎着床前基因检测市场（按检测交付类型、检测类型、技术类型、产品和最终用户划分）—2025-2030 年全球预测

Preimplantation Genetic Testing Market by Testing Type, Test Type, Technology Type, Offering, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年胚胎着床前基因检测市值将达到 7.8019 亿美元，到 2025 年将以 12.23% 的复合年增长率增长至 8.7374 亿美元，到 2030 年将达到 15.5987 亿美元。

主要市场统计数据
基准年2024年 7.8019亿美元
预计年份：2025年 8.7374亿美元
预测年份 2030 15.5987亿美元
复合年增长率（%） 12.23%

胚胎着床前基因检测（PGT）已成为生殖医学变革的支柱，为人类发展的早期阶段带来了希望和清晰的认识。如今，基因筛检和诊断技术的进步使得在胚胎着床前识别潜在的基因异常成为可能，从而降低遗传疾病的风险并确保更健康的结果。在个人化医疗和针对性诊断需求日益增长的时代，这一发展尤其重要。

PGT技术的演变受到临床研究数量的增加、检测技术的改进以及生物技术公司和医疗中心之间合作的加强的推动。随着生育诊所和诊断实验室采用尖端的基因筛检工具，技术创新提高了可近性和效率，情况正在迅速改变。在这种动态环境中，鼓励相关人员探索强大的基因检测通讯协定，并采用利用亲代和胚胎遗传学最新见解的综合策略。

因此，市场呈现上升趋势，加强了研究倡议，并使得生殖保健方法更加全面。每项技术突破都有望提高生育治疗的安全性和成功率，使临床医生和患者都能更轻鬆地完成治疗。

改变胚胎着床前基因检测市场

近年来，发生了一系列变革，重新定义了胚胎着床前基因检测市场的轮廓。该行业采用了尖端技术和方法，大大提高了基因筛检的准确性和可靠性。这个领域历来依赖标准细胞遗传学方法，现在正采用高解析度基因组工具，导致诊断准确性和吞吐量的模式转移。

最显着的进步之一是次世代定序仪的整合。该技术不仅提高了对轻微染色体异常的检测能力，而且还能够以无与伦比的精度同时检测多种遗传疾病。此外，从传统的聚合酵素链锁反应（PCR）的测试到更复杂的基因组杂合反应技术的演变，创造了增强临床信心的环境。

全球法律规范也不断发展以适应这些进步。新的指南越来越认识到基因组完整性的重要性以及全面、高保真胚胎着床前测试的必要性。此外，公共研究机构和私人公司之间加强合作正在为整个行业创造协同效应并刺激进一步的创新。由于这种模式转移，市场正在走向更有效、个人化治疗方法和改善患者治疗效果的时代。

胚胎着床前基因检测市场的关键细分洞察

仔细观察市场区隔就会发现一个微妙的图景，反映出多样化的检测技术、先进的技术和多样化的最终用途。按测试类型细分，检视 PGT-A（涵盖非整倍体监测）、PGT-M（专注于检测单基因疾病）和 PGT-SR（旨在分析结构重排）的市场。由于有效诊断所需的特异性和准确性，每个类别都呈现出独特的挑战和机会。

此外，按检测类型划分，可分为胚胎着床前基因诊断和胚胎着床前基因筛检，前者主要用于检测高风险夫妇中已知的基因或染色体异常，后者对胚胎中潜在的基因异常进行更广泛的调查。这两种方法可以有效地筛检多种遗传疾病，并根据不同患者的需求提供量身定制的解决方案。

在技​​术领域，市场细分涵盖一系列技术，从比较基因组杂合反应和萤光原位杂合技术到下一代定序、基于 PCR 的测试和单核苷酸多态性分析。这些方法的进步显着提高了基因检测方法的准确性、可扩展性和可负担性。对先进技术的依赖程度不断提高不仅提高了诊断的准确性，也为进一步的科学创新铺平了道路。

另一个重要方面是按产品细分，透过仪器、试剂、消耗品和专用软体的视角来审视市场。这些组件构成了检查过程的支柱，每个环节的进步都凸显了自动化和资料分析的主要趋势。

最后，从最终用户的观点来看，市场已经涵盖诊断实验室、生育诊所、医院和研究机构。随着不同营业单位越来越多地寻求临床效率和技术复杂性之间的平衡，这种细分加强了 PGT 技术的广泛应用。了解这种多方面的细分模型将有助于相关人员了解市场趋势、策略性地分配资源并推动生殖保健这一关键领域的进一步创新。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 改善医疗保健基础设施并增加世界各地基因检测设施的使用机会
      • 体外受精 (IVF) 程序和胚胎着床前基因检测的需求增加
      • 提高准父母对遗传疾病及其预防的认识
    • 限制因素
      • 胚胎着床前基因检测程序的高成本限制了其广泛普及和采用
    • 机会
      • 技术进步提高了胚胎着床前基因检测的准确性和速度
      • 与 IVF 诊所合作提供配套服务
    • 任务
      • 遵守各种当地法规和道德标准
  • 市场区隔分析
    • 检测类型：PGT-M 预防遗传疾病传播的需求日益增加
    • 最终用户：生育诊所越来越多地使用胚胎着床前基因检测来提高 IVF 成功率
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章胚胎着床前基因检测市场（依检测类型划分）

  • 介绍
  • PGT-A（非整倍体）
  • PGT-M（单基因疾病）
  • PGT-SR（结构重组）

第七章胚胎着床前基因检测市场（依检测类型）

  • 介绍
  • 胚胎着床前基因诊断
  • 胚胎胚胎着床前基因筛检

第八章胚胎着床前基因检测市场（依技术类型）

  • 介绍
  • 比较基因组杂合反应
  • 萤光原位杂合技术
  • 下一代定序
  • PCR检测
  • 单核苷酸多态性

第九章胚胎着床前基因检测市场（依产品提供）

  • 介绍
  • 装置
  • 试剂和耗材
  • 软体

第 10 章 胚胎胚胎着床前基因检测市场（依最终用户划分）

  • 介绍
  • 诊断实验室
  • 不孕不育诊所
  • 医院
  • 研究所

第 11 章美洲胚胎着床前基因检测市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区胚胎胚胎着床前基因检测市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲胚胎着床前基因检测市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Techne Corporation
  • Bioarray SL
  • EUROPE IVF International sro
  • F. Hoffmann-La Roche AG
  • Genea Limited
  • GENETiKS
  • Illumina, Inc.
  • Invicta Genetics
  • Invitae Corporation
  • Juno Genetics, US Inc.
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Merck KGaA
  • Natera, Inc.
  • NextGen Genetics Holdings, LLC
  • Ovation Fertility
  • PacGenomics
  • PerkinElmer, Inc.
  • Progyny, Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations, LLC
  • SEQUENCE46, LLC
  • Sysmex Corporation
  • Takara Bio Inc.
  • The Cooper Companies Inc.
  • Thermo Fisher Scientific Inc.
  • Vitrolife Sweden AB
  • Yikon Genomics（Shanghai）Co., Ltd.
Product Code: MRR-030EE48515DA

The Preimplantation Genetic Testing Market was valued at USD 780.19 million in 2024 and is projected to grow to USD 873.74 million in 2025, with a CAGR of 12.23%, reaching USD 1,559.87 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 780.19 million
Estimated Year [2025] USD 873.74 million
Forecast Year [2030] USD 1,559.87 million
CAGR (%) 12.23%

Preimplantation Genetic Testing (PGT) has emerged as a transformative pillar in reproductive medicine, offering hope and clarity at the earliest stages of human development. Advances in genetic screening and diagnostic techniques have made it possible to identify potential genetic anomalies before implantation, thereby mitigating the risk of inherited disorders and ensuring healthier outcomes. This development is particularly significant in an era where the demand for personalized medicine and targeted diagnostics is intensifying.

The evolution in PGT technologies is driven by an ever-growing body of clinical research, improvements in laboratory techniques, and increased collaboration among biotechnology firms and healthcare institutions. As both fertility clinics and diagnostic laboratories incorporate state-of-the-art genetic screening tools, the landscape is evolving rapidly, with innovation leading to greater accessibility and efficiency. In this dynamic environment, stakeholders are encouraged to explore robust genetic testing protocols and adopt integrative strategies that leverage the latest insights in parental and embryonic genetics.

The market has thus witnessed an upward trajectory, bolstering research initiatives and enabling a more comprehensive approach to reproductive health. With each technological breakthrough, the promise of improved safety and higher success rates in fertility treatments becomes increasingly attainable for clinicians and patients alike.

Transformative Shifts in the Preimplantation Genetic Testing Landscape

Recent years have seen a series of transformative shifts that have redefined the contours of the preimplantation genetic testing market. The industry has embraced cutting-edge technologies and methodologies that have significantly improved the precision and reliability of genetic screenings. Historically reliant on standard cytogenetic techniques, the field has now incorporated high-resolution genomic tools, leading to a paradigm shift in diagnostic accuracy and throughput.

One of the most notable advancements has been the integration of next-generation sequencing. This technology not only enhances the detection of minor chromosomal aberrations but also enables simultaneous testing for multiple genetic conditions with unmatched precision. Additionally, the evolution from traditional polymerase chain reaction (PCR)-based testing to more sophisticated genomic hybridization techniques has fostered an environment of enhanced clinical reliability.

Regulatory frameworks on a global scale are also shifting to accommodate these advancements. Newer guidelines are increasingly acknowledging the importance of genomic integrity and the necessity for comprehensive, high-fidelity preimplantation testing. Furthermore, improved collaboration between public research institutions and private enterprises has led to industry-wide synergy, spurring further innovation. The resulting paradigm shifts have, therefore, propelled the market towards an era of higher efficacy, tailored treatment modalities, and improved patient outcomes.

Key Segmentation Insights of the Preimplantation Genetic Testing Market

An in-depth examination of market segmentation reveals a nuanced landscape reflective of diverse testing techniques, advanced technologies, and varied end-use applications. The segmentation based on testing type examines the market across PGT-A, which targets aneuploidy investigation, PGT-M focused on monogenic disorder detection, and PGT-SR, designed to analyze structural rearrangements. Each category illustrates unique challenges and opportunities, driven by the specificity and accuracy required for effective diagnosis.

Furthermore, the division based on test type differentiates between preimplantation genetic diagnosis, primarily employed for detecting known genetic or chromosomal anomalies in high-risk couples, and preimplantation genetic screening, which provides a broader survey of potential genetic irregularities in embryos. This dual approach ensures that a wide range of genetic conditions can be effectively screened, offering tailored solutions for diverse patient needs.

In the realm of technology, the market segmentation covers an array of methodologies, from comparative genomic hybridization and fluorescent in-situ hybridization to next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism analysis. Advancements in these methods have significantly elevated the precision, scalability, and affordability of genetic testing procedures. The growing reliance on high-throughput technologies has not only enhanced diagnostic accuracy but has also paved the way for further scientific innovations.

Another critical aspect is the segmentation based on offerings, which scrutinizes the market through the lens of instruments, reagents and consumables, and specialized software. These components form the backbone of the testing process, and advancements in each segment underscore the progressive trends in automation and data analytics.

Finally, when considering the end-user perspective, the market is studied across diagnostic laboratories, fertility clinics, hospitals, and research institutes. This segmentation reinforces the wide adoption of PGT technologies, as diverse entities increasingly seek to balance clinical efficiency with technological sophistication. By understanding these multifaceted segmentation models, stakeholders can ascertain market trends, allocate resources strategically, and drive further innovation within this critical area of reproductive medicine.

Based on Testing Type, market is studied across PGT-A (Aneuploidy), PGT-M (Monogenic Disorders), and PGT-SR (Structural Rearrangements).

Based on Test Type, market is studied across Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.

Based on Technology Type, market is studied across Comparative Genomic Hybridization, Fluorescent In-Situ Hybridization, Next-Generation Sequencing, PCR-Based Testing, and Single-Nucleotide Polymorphism.

Based on Offering, market is studied across Instruments, Reagents & Consumables, and Software.

Based on End User, market is studied across Diagnostic Laboratories, Fertility Clinics, Hospitals, and Research Institutes.

Key Regional Insights of the Global Preimplantation Genetic Testing Market

The regional dynamics of the preimplantation genetic testing market reveal a rich tapestry of growth patterns, regulatory environments, and technological adoption across various geographical areas. In the Americas, a combination of robust healthcare infrastructure, significant investments in biotechnology, and progressive public health policies has resulted in rapid market expansion. The region represents a hub of clinical excellence and technological adoption, making it one of the most dynamic players in the global scenario.

Across Europe, the Middle East, and Africa, the market is characterized by a balanced mix of established healthcare systems and emerging markets. Here, stringent regulatory standards coupled with a surge in demand for precision diagnostics drive advancements and innovation. This area, while facing varied challenges, also presents significant opportunities through public-private partnerships and enhanced cross-border collaborations, which act as catalysts for market growth.

In the Asia-Pacific region, rapid urbanization, increasing awareness about reproductive health, and soaring investments in healthcare technologies have contributed to a vibrant market landscape. The convergence of technological know-how and increased demand for elite medical services has made this region a fertile ground for the adoption of preimplantation genetic testing. As healthcare systems in these regions continue to evolve, the market is anticipated to benefit from an influx of new players and innovative diagnostic solutions, further reinforcing its potential on the global stage.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Preimplantation Genetic Testing Market

The competitive landscape in the preimplantation genetic testing market is marked by a diverse array of global players, each contributing to the rapid evolution of diagnostic technologies and clinical methodologies. Companies such as Abbott Laboratories and Agilent Technologies, Inc. have been front-runners, leveraging extensive research and innovation to deliver advanced genetic testing solutions. Their efforts are complemented by the expertise of organizations like Bio-Techne Corporation and Bioarray S.L., who continue to push the envelope in assay development and genomic analytics.

Emerging as significant competitors, enterprises such as EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, and Genea Limited have established a formidable presence in the sector through integrated platforms that combine clinical diagnostics with next-generation sequencing. GENETiKS, Illumina, Inc., and Invicta Genetics have further revolutionized the market by streamlining data analysis and enhancing the precision of genetic screenings.

Invitae Corporation and Juno Genetics, US Inc. are noteworthy for their contributions in facilitating accessible genetic diagnostics, while Laboratory Corporation of America Holdings and MedGenome Labs Ltd. have been instrumental in bridging the gap between cutting-edge research and clinical application. In addition, established giants such as Merck KGaA, Natera, Inc., and NextGen Genetics Holdings, LLC have strategically expanded their service portfolios to include a range of sophisticated genetic testing options.

Alongside these, companies like Ovation Fertility, PacGenomics, PerkinElmer, Inc., and Progyny, Inc. have garnered significant attention for their innovations in fertility-focused genetic diagnostics. Qiagen N.V., Quest Diagnostics Incorporated, and Reproductive Genetic Innovations, LLC have further fortified the market with robust testing solutions, while SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., and The Cooper Companies Inc. lead efforts in integrating software advancements with biological testing. Not to be overlooked, Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd. round out a competitive landscape where collaborative innovation drives both technological improvements and market penetration.

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders seeking to navigate the evolving landscape of preimplantation genetic testing successfully, several actionable recommendations stand out. One key strategy is to prioritize investment in research and development. By allocating resources to advanced genomic technologies, companies can not only enhance diagnostic accuracy but also pioneer breakthrough applications that address emerging clinical needs. Embracing innovation in next-generation sequencing and complementary technologies can facilitate the creation of more robust, user-friendly testing platforms.

Moreover, fostering collaborative partnerships between diagnostic laboratories, research institutions, and clinical service providers will be crucial in accelerating product development and streamlining regulatory pathways. Industry leaders should also focus on integrating digital solutions and artificial intelligence to optimize both data management and interpretation. By doing so, the process of genomic analysis can be made more efficient, leading to faster turnaround times and more personalized patient care.

Another critical recommendation is to enhance market penetration through strategic geographic expansion. By investing in regions with high growth potential, such as emerging markets in the Asia-Pacific and the rapidly evolving sectors in Europe, Middle East, and Africa, companies can tap into an expanding customer base. Aligning product lines with local regulatory frameworks and clinical needs will further ensure that innovations are well received in diverse markets.

Finally, it is imperative to maintain stringent quality control measures and adhere to international regulatory standards. This not only instills confidence among end-users but also fosters a competitive environment based on safety, accuracy, and superior clinical outcomes. By implementing these recommendations, industry leaders can position themselves at the forefront of an increasingly competitive and technologically advanced market.

Conclusion: The Future of Preimplantation Genetic Testing

Preimplantation genetic testing is positioned at the crossroads of rapid technological evolution and pressing clinical demand. The market is thriving due to substantial advancements in genomic technology and a clearer understanding of genetic disorders that affect reproductive health. With transformative shifts in testing methodologies and an expansive segmentation framework covering various technological and application-based arenas, the market stands to benefit from both incremental and disruptive innovations.

Globally, the market is supported by vigorous regional dynamics, with significant growth observed in the Americas, Europe, Middle East & Africa, and Asia-Pacific. Each of these regions offers unique opportunities based on their regulatory frameworks, economic environments, and healthcare infrastructures. As innovative companies continue to push boundaries, the landscape has become increasingly competitive, encouraging continuous improvement and cross-sector collaboration.

Ultimately, the future of preimplantation genetic testing is one marked by increased accuracy, efficiency, and accessibility. The cumulative effect of technological advancements, broader market segmentation, and proactive regional expansion strategies promises to redefine reproductive health care. Stakeholders who embrace these trends and invest in future-focused strategies are likely to reap substantial long-term benefits, driving both improved patient outcomes and sustainable market growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Improving healthcare infrastructure and easier access to genetic testing facilities worldwide
      • 5.1.1.2. Growing demand for in-vitro fertilization (IVF) procedures requiring preimplantation genetic testing
      • 5.1.1.3. Increasing awareness about genetic disorders and their prevention among prospective parents
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of preimplantation genetic testing procedures limiting widespread accessibility and adoption
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements enhancing accuracy and speed in preimplantation genetic testing
      • 5.1.3.2. Collaborations with IVF clinics to offer bundled preimplantation genetic testing services
    • 5.1.4. Challenges
      • 5.1.4.1. Compliance with different regional regulations and ethical standards
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Testing Type: Increasing need for PGT-M to prevent transmitting hereditary conditions
    • 5.2.2. End User: Growing utilization of preimplantation genetic testing in fertility clinics to enhance the success rates of in vitro fertilization
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Preimplantation Genetic Testing Market, by Testing Type

  • 6.1. Introduction
  • 6.2. PGT-A (Aneuploidy)
  • 6.3. PGT-M (Monogenic Disorders)
  • 6.4. PGT-SR (Structural Rearrangements)

7. Preimplantation Genetic Testing Market, by Test Type

  • 7.1. Introduction
  • 7.2. Preimplantation Genetic Diagnosis
  • 7.3. Preimplantation Genetic Screening

8. Preimplantation Genetic Testing Market, by Technology Type

  • 8.1. Introduction
  • 8.2. Comparative Genomic Hybridization
  • 8.3. Fluorescent In-Situ Hybridization
  • 8.4. Next-Generation Sequencing
  • 8.5. PCR-Based Testing
  • 8.6. Single-Nucleotide Polymorphism

9. Preimplantation Genetic Testing Market, by Offering

  • 9.1. Introduction
  • 9.2. Instruments
  • 9.3. Reagents & Consumables
  • 9.4. Software

10. Preimplantation Genetic Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Fertility Clinics
  • 10.4. Hospitals
  • 10.5. Research Institutes

11. Americas Preimplantation Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Successful PGT-HLA procedure at Jindal IVF offers hope for families facing genetic challenges
    • 14.3.2. Strategic GenEmbryomics and Progenesis partnership pioneers IVF testing with groundbreaking genetic innovations
    • 14.3.3. Natera Inc. to acquire prenatal and carrier screening assets from Invitae, to enhance patient services and market position
    • 14.3.4. Thermo Fisher Scientific launches advanced sequencing tools for preimplantation genetic testing, enhancing fertility research and reproductive health outcomes
    • 14.3.5. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
    • 14.3.6. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
    • 14.3.7. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
    • 14.3.8. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
    • 14.3.9. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
    • 14.3.10. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Bio-Techne Corporation
  • 4. Bioarray S.L.
  • 5. EUROPE IVF International s.r.o.
  • 6. F. Hoffmann-La Roche AG
  • 7. Genea Limited
  • 8. GENETiKS
  • 9. Illumina, Inc.
  • 10. Invicta Genetics
  • 11. Invitae Corporation
  • 12. Juno Genetics, US Inc.
  • 13. Laboratory Corporation of America Holdings
  • 14. MedGenome Labs Ltd.
  • 15. Merck KGaA
  • 16. Natera, Inc.
  • 17. NextGen Genetics Holdings, LLC
  • 18. Ovation Fertility
  • 19. PacGenomics
  • 20. PerkinElmer, Inc.
  • 21. Progyny, Inc.
  • 22. Qiagen N.V.
  • 23. Quest Diagnostics Incorporated
  • 24. Reproductive Genetic Innovations, LLC
  • 25. SEQUENCE46, LLC
  • 26. Sysmex Corporation
  • 27. Takara Bio Inc.
  • 28. The Cooper Companies Inc.
  • 29. Thermo Fisher Scientific Inc.
  • 30. Vitrolife Sweden AB
  • 31. Yikon Genomics (Shanghai) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET MULTI-CURRENCY
  • FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET MULTI-LANGUAGE
  • FIGURE 3. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 4. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 239. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024